Targeting Mfrn2 to Inhibit Metastatic Cancers

Informacje na temat projektu

MetaIron

Identyfikator umowy o grant: 101112780

DOI

10.3030/101112780

Projekt został zamknięty

Data podpisania przez KE 1 Marca 2023

Data rozpoczęcia 1 Czerwca 2023

Data zakończenia 30 Listopada 2024

Finansowanie w ramach

• European Research Council (ERC)

Koszt całkowity

Brak danych

Wkład UE

€ 150 000,00

Koordynowany przez

VIB VZW
Belgium

Periodic Reporting for period 1 - MetaIron (Targeting Mfrn2 to Inhibit Metastatic Cancers)

Okres sprawozdawczy: 2023-06-01 do 2024-11-30

Podsumowanie kontekstu i ogólnych celów projektu

The majority of cancer patients dies due to metastasis formation in distant organs. To date, we unfortunately largely lack effective therapies for preventing or treating an already developed metastatic disease. The effect of this lack of treatment options against metastatic cancers is dramatically illustrated for breast cancer. At early-stage disease the 5-year survival rate for breast cancer patients is more than 90%, however, once metastases arise this drops to less than 20%, resulting in over 685,000 deaths per year. Thus, there is an urgent need to develop novel therapeutic options that can prevent or treat metastases in multiple organs. We evaluated targeting iron metabolism to inhibit metastasis growth.

Prace wykonane od początku projektu do końca okresu sprawozdawczego oraz najważniejsze dotychczasowe rezultaty

We investigated Mfrn2 (SLC25A28) as a drug target against metastases. Mfrn2 is a mitochondrial iron transporter. A patent application for the use of Mfrn2 as a drug target was filed (EP 21216949.4.). Assays to screen for Mfrn2 inhibitors were researched. In collaboration with the EU funded RESOLUTE consortium drug screens were performed and candidates ranked. Further mouse experiments were performed. The relation of iron levels to distant metastasis was evaluated in a cohort of patients (manuscript in revision). Overall, we concluded that iron metabolism is an important drug target but that the nature of Mfrn2 as solute carrier remains challenging to develop isoform selective therapies.

Innowacyjność oraz oczekiwany potencjalny wpływ (w tym dotychczasowe znaczenie społeczno-gospodarcze i szersze implikacje społeczne projektu)

We established collaborations and interactions with the EU funded consortium RESOLUTE.